![]() ![]() It is expected to be completed by September 2024. The clinical trial is still active to understand the additional benefit of the drug in the long run. The data further demonstrated that the benefit-to-risk ratio improved with the duration of treatment. In 2007, analysis of follow-up data showed that the drug’s benefits stayed the same even after ten years while the side effects did not increase even after five years of treatment. A follow-up of the trial participants was considered essential to establish tamoxifen’s efficacy in prevention. The data, however, did not reveal the benefit-to-risk ratio of tamoxifen in the prevention of breast cancer. Initial results declared in 2002 revealed that the drug reduced breast cancer incidence by 31%, but caused serious side effects such as thromboembolism. ![]() Patients were administered with either 20mg tablets of tamoxifen citrate or placebo daily for five years. The trial enrolled 7,154 women aged 35-70 years across nine countries to investigate if tamoxifen, a hormonal drug, can prevent the development of breast cancer in high-risk women. The UK’s Queen Mary University of London initiated a phase three clinical trial titled Tamoxifen for the Prevention of Breast Cancer in High-Risk Women (IBIS-1) in January 1994. Tamoxifen for Breast Cancer – January 1994 till date Queen Mary University of London initiated a clinical trial titled Tamoxifen for the Prevention of Breast Cancer in High-Risk Women (IBIS-1) in January 1994. ![]() Botulinum Toxin for involuntary movement disorders 10. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |